NCT07184385Not yet recruitingPhase 3
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition
Source: ClinicalTrials.gov · Last updated 23 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Sept 2025
- Start date
- Mar 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- StemCyte, Inc.
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07184385
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 60
- From Mar 2026 to the primary completion date, Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Neurological disorders prior to COVID-19 diagnosis
- Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening
- Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
Other illness
- With pre-existing terminal illness
- With known immune disease
- Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
- Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters
Other
- Is pregnant or breastfeeding
Who the study is looking for
- Male or female aged ≥ 18
- With post-COVID condition
- Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
- Able to provide signed informed consent (by the subject or his/her legally authorized representative)
- Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.